Oxcarbazepin, a widely-used antiepileptic treatment is evaluated with respect to Cortisol-degradation. Young adults and adults with oxcarbazepine monotherapy since at least 6 months and temporal lobe epilepsy are eligible to participate.Therefore 24-h-Urine has to be collected and degradation products are measured.
Conditions
Interventions
Trade Name: Trileptal
Product Name: Oxcarbazepin
Pharmaceutical Form: Tablet
Sponsors
Medical University Innsbruck
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Young adults (>14 yrs, post-puberty) and adults with oxcarbazepine monotherapy since at least 6 months. Temporal-lobe epilepsy with no other cerebral malformations. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: <14 years. Other types of epilepsy. Cerebral Malformations. combination therapy. Other endocrine disorders, especially endocrine or other disorders requiring cortisone therapy (e.g. mb. addison).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Degradation products of endogenous cortisol (e.g. 6OH-Cortisol) in 24-h-urine in patients with temporal lobe epilepsy with oxcarbazepine monotherapy.;Secondary Objective: ;Primary end point(s): total degradation markers of endogenous cortisol in patients. | — |
Countries
Austria
Outcome results
None listed